Amgen Inc.
Long

🔬💊 Amgen Innovations & Strategic Moves 🚀

152
🌟 Lumakras Breakthrough:
Amgen (AMGN) pioneers cancer treatment with Lumakras, the first medication targeting a mutation found in approximately 13% of lung cancer patients.

💰 Strategic Acquisition:
Amgen acquires Horizon Therapeutics for a substantial $28 billion in cash.
Incorporates Tepezza, an FDA-approved medicine for thyroid eye disease, into Amgen's product portfolio.

📈 Market Outlook:
Bullish stance on AMGN suggests support levels above $260.00-$265.00.
Anticipated upside target in the range of $360.00-$365.00.

Exciting developments in biotech and strategic expansion for Amgen! 🌐💉

#AmgenInnovation #Biotech #StockMarket 📰📊

Clause de non-responsabilité

Les informations et publications ne sont pas destinées à être, et ne constituent pas, des conseils ou recommandations financiers, d'investissement, de trading ou autres fournis ou approuvés par TradingView. Pour en savoir plus, consultez les Conditions d'utilisation.